SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
BOSTON and ROLLE, Switzerland, April 29, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with...
SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC
BOSTON, MA and ROLLE, Switzerland, March 18, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles...
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI healthcare technology and a leader in...
SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities
The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving genomic cancer drivers BOSTON, MA and ROLLE, Switzerland, Jan. 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare...
SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024
Launch of new application enables global access to highly recognized solid tumor profiling assay BOSTON and ROLLE, Switzerland, Nov. 21, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven...